Shigellosis News and Research

RSS

Clinical study supports the long-lasting impacts of typhoid conjugate vaccine

A single dose of the typhoid conjugate vaccine, Typbar TCV, provides lasting efficacy in preventing typhoid fever in children ages 9 months to 12 years old, according to a new study conducted by researchers at University of Maryland School of Medicine's (UMSOM) Center for Vaccine Development and Global Health (CVD) and led by in-country partners at the Malawi-Liverpool Wellcome Trust (MLW) Clinical Research Programme.

25 Jan 2024

The international spread of drug-resistant Shigella sonnei

Researchers examined the international dissemination of the outbreak of extensively drug-resistant Shigella sonnei.

12 Apr 2023

Increase in resistant Shigella infections among men who have sex with men

Researchers report a rise in Shigella flexneri type 2a infections in men who have sexual intercourse with men in England from September 2021 onward.

7 Feb 2023

Study demonstrates safety and efficacy of a three-dose whole-parasite vaccine against malaria

A three-dose regimen of a whole-parasite vaccine against malaria – called Plasmodium falciparum sporozoite (PfSPZ) vaccine – demonstrated safety and efficacy when tested in adults living in Burkina Faso, West Africa, which has endemic malaria.

4 Jan 2023

Did COVID-19 mitigation measures in the United Kingdom impact the transmission of other infectious diseases?

Researchers explored the impact of the coronavirus disease 2019 (COVID-19) pandemic-associated non-pharmaceutical prevention measures on the transmission of 22 infectious diseases in England.

25 Oct 2022

Researchers develop new technique to keep drinking water safe at refugee settlements

Waterborne illness is one of the leading causes of infectious disease outbreaks in refugee and internally displaced persons (IDP) settlements, but a team led by York University has developed a new technique to keep drinking water safe using machine learning, and it could be a game changer.

6 Sep 2022

UTSW researchers show how vulnerable cells armor themselves against infection

Cells in some of the body's most vulnerable entry routes to bacterial infection buffer themselves when the immune system detects danger by reorganizing the cholesterol on their surfaces, a new study led by UTSW scientists suggests.

13 Apr 2020

UMSOM research shows even milder cases of diarrheal diseases can lead to child mortality

Diarrheal diseases are a leading cause of death for young children, accounting for nine percent of all deaths worldwide in children under five years of age, with most occurring in children under two years of age.

9 Jan 2020

Certain bacteria can override programmed cell death

Certain bacteria can override a defense mechanism of the immune system, so called programmed cell death, through inhibition of death effector molecules by their outer membranes components.

26 Dec 2019

Antibiotic-resistant shigella strain cases soar in Australia

A drug-resistant strain of a highly contagious sexually-transmitted bowel infection spreads in Victoria, Australia, with a vast majority of cases happening in men who have sex with men.

19 Dec 2019

UMSOM researchers to test the safety, tolerability of prototype Shigella-ETEC vaccine

Each year, millions of people contract serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli, and researchers at the University of Maryland School of Medicine are testing a vaccine designed to offer protection against these serious pathogens.

10 Dec 2019

Early adherence step in intestinal transit of Shigella discovered

The bacterial pathogen Shigella, often spread through contaminated food or water, is a leading cause of mortality in both children and older adults in the developing world.

4 Dec 2019

UMSOM receives landmark contract from NIAID for influenza research

Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases, with total funding up to more than $200 million over seven years if all contract options are exercised.

20 Sep 2019

New study launched in Burkina Faso to test typhoid conjugate vaccine

A new study has been launched in Burkina Faso for Bharat Biotech's typhoid conjugate vaccine. It is the second clinical study underway in Africa for the vaccine and the first in West Africa.

4 Dec 2018

Unrecognized childhood infections far greater threat than previously realized

Children around the world are suffering from unnoticed infections that are stunting their growth and mental development, new research from an international coalition of scientists reveals.

10 Oct 2018

First African child vaccinated with new typhoid conjugate vaccine

Today the University of Maryland School of Medicine's Center for Vaccine Development is proud to be part of vaccine history in Africa.

22 Feb 2018

Genomic sequencing reveals new insights into major shigellosis outbreaks in California

In a study that could have significant impact on how disease outbreaks are managed, researchers at UC Davis and the California Department of Public Health have sequenced and analyzed genomes from Shigella sonnei (S. sonnei) bacteria associated with major shigellosis outbreaks in California in 2014 and 2015.

23 Dec 2016

New research shows childhood diarrhea cases significantly higher than estimated

The number of cases of childhood diarrhoea attributable to pathogens (bacteria, parasites, viruses or other infections) have been substantially underestimated and may be nearly twice as high as previous analysis suggests, according to new research published in The Lancet.

24 Sep 2016

UM SOM selected as study site for human safety trial of new Zika vaccine

As world leaders increasingly recognize the Zika virus as an international public health threat, the Center for Vaccine Development at the University of Maryland School of Medicine's Institute for Global Health has been chosen as one of three study sites in a human safety trial of a new Zika vaccine.

7 Aug 2016

International travelers bring multidrug-resistant shigellosis to the US

International travelers are bringing a multidrug-resistant intestinal illness to the United States and spreading it to others who have not traveled, according to a report released today by the Centers for Disease Control and Prevention (CDC).

3 Apr 2015